文献速递血脂与心血管预防冠心病

非洲裔美国人的亚临床动脉粥样硬化、他汀类药物适用性与结局:杰克逊心脏研究

Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study.
PubMed 文献 · JAMA Cardiol · 2017-01-01

该前瞻性社区研究纳入2812名40至75岁无动脉粥样硬化性心血管疾病(ASCVD)的非洲裔美国人,比较USPSTF与ACC/AHA指南识别亚临床及临床ASCVD的准确性。USPSTF指南识别出55.2%的冠状动脉钙化(CAC)评分大于0者,ACC/AHA指南识别出69.3%。USPSTF指南未推荐治疗近25%的ACC/AHA指南认为有他汀适应症且存在血管钙化、ASCVD风险低至中等的非洲裔美国人。

要点

  • ACC/AHA指南识别CAC评分大于0的非洲裔美国人比例高于USPSTF指南(69.3% vs 55.2%)。
  • USPSTF指南未推荐治疗近25%的ACC/AHA指南认为有他汀适应症且存在血管钙化的非洲裔美国人。
  • ACC/AHA指南他汀适应症者中,有CAC者10年ASCVD发生率高于无CAC者(8.1 vs 3.1每1000人年)。

核心结论

  • USPSTF指南将治疗推荐集中于38%的高危非洲裔美国人,代价是未推荐治疗近25%的ACC/AHA指南认为有他汀适应症且存在血管钙化、ASCVD风险低至中等的非洲裔美国人。

研究设计与样本

  • 前瞻性、社区基础研究,纳入2812名40至75岁无 prevalent ASCVD 的非洲裔美国人进行ASCVD风险评估,其中1743名完成计算机断层扫描。

主要发现

  • USPSTF指南识别出404/732名(55.2%)CAC评分大于0的非洲裔美国人,ACC/AHA指南识别出507名(69.3%)(风险差14.1%;95%CI 11.2-17.0;P<.001)。
  • 两指南的他汀推荐均与CAC评分大于0相关(OR 5.1;95%CI 4.1-6.3;P<.001)。
  • 两指南均推荐他汀者心血管事件率为9.6/1000患者年,仅ACC/AHA指南推荐他汀者为低至中等风险(4.1事件/1000患者年)。
  • ACC/AHA指南他汀适应症者中,有CAC者10年ASCVD发生率为8.1/1000人年(95%CI 5.9-11.1),无CAC者为3.1/1000人年(95%CI 1.6-5.9)(P=.02)。
  • USPSTF指南他汀适应症者中有CAC者10年ASCVD事件率未显著更高;USPSTF指南非他汀适应症者中有CAC者ASCVD事件率高于无CAC者(2.8/1000人年;95%CI 1.5-5.4 vs 0.8/1000人年;95%CI 0.3-1.7)(P=.03)。

关键数值与推荐

  • USPSTF指南识别CAC评分大于0的非洲裔美国人比例为55.2%(404/732),ACC/AHA指南为69.3%(507名),风险差14.1%(95%CI 11.2-17.0;P<.001)。
  • 两指南他汀推荐与CAC评分大于0的OR为5.1(95%CI 4.1-6.3;P<.001)。
  • ACC/AHA指南他汀适应症者中,有CAC者10年ASCVD发生率8.1/1000人年(95%CI 5.9-11.1),无CAC者3.1/1000人年(95%CI 1.6-5.9)(P=.02)。
  • USPSTF指南非他汀适应症者中,有CAC者ASCVD事件率2.8/1000人年(95%CI 1.5-5.4),无CAC者0.8/1000人年(95%CI 0.3-1.7)(P=.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Modern prevention guidelines substantially increase the number of individuals who are eligible for treatment with statins. Efforts to refine statin eligibility via coronary calcification have been studied in white populations but not, to our knowledge, in large African American populations. OBJECTIVE: To compare the relative accuracy of US Preventive Services Task Force (USPSTF) and American College of Cardiology/American Heart Association (ACC/AHA) recommendations in identifying African American individuals with subclinical and clinical atherosclerotic cardiovascular disease (ASCVD). DESIGN, SETTING, AND PARTICIPANTS: In this prospective, community-based study, 2812 African American individuals aged 40 to 75 years without prevalent ASCVD underwent assessment of ASCVD risk. Of these, 1743 participants completed computed tomography. MAIN OUTCOMES AND MEASURES: Nonzero coronary artery calcium (CAC) score, abdominal aortic calcium score, and incident ASCVD (ie, myocardial infarction, ischemic stroke, or fatal coronary heart disease). RESULTS: Of the 2812 included participants, the mean (SD) age at baseline was 55.4 (9.4) years, and 1837 (65.3%) were female. The USPSTF guidelines captured 404 of 732 African American individuals (55.2%) with a CAC score greater than 0; the ACC/AHA guidelines identified 507 individuals (69.3%) (risk difference, 14.1%; 95% CI, 11.2-17.0; P < .001). Statin recommendation under both guidelines was associated with a CAC score greater than 0 (odds ratio, 5.1; 95% CI, 4.1-6.3; P < .001). While individuals indicated for statins under both guidelines experienced 9.6 cardiovascular events per 1000 patient-years, those indicated under only ACC/AHA guidelines were at low to intermediate risk (4.1 events per 1000 patient-years). Among individuals who were statin eligible by ACC/AHA guidelines, the 10-year ASCVD incidence per 1000 person-years was 8.1 (95% CI, 5.9-11.1) in the presence of CAC and 3.1 (95% CI, 1.6-5.9) without CAC (P = .02). While statin-eligible individuals by USPSTF guidelines did not have a significantly higher 10-year ASCVD event rate in the presence of CAC, African American individuals not eligible for statins by USPSTF guidelines had a higher ASCVD event rate in the presence of CAC (2.8 per 1000 person-years; 95% CI, 1.5-5.4) relative to without CAC (0.8 per 1000 person-years; 95%, CI 0.3-1.7) (P = .03). CONCLUSIONS AND RELEVANCE: The USPSTF guidelines focus treatment recommendations on 38% of high-risk African American individuals at the expense of not recommending treatment in nearly 25% of African American individuals eligible for statins by ACC/AHA guidelines with vascular calcification and at low to intermediate ASCVD risk.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Shah RV, Spahillari A, Mwasongwe S, et al. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study. JAMA Cardiol. 2017. PMID: 28315622. doi:10.1001/jamacardio.2017.0944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。